NL-OMON20337已完成不适用
A Phase I Study to assess in vitro and in vivo immunoreactivity of Ruconest in Subjects with cow's milk allergy (CMA) and/or rabbit allergy (RA).
Pharming Technologies BV (Performer: University Medical Center Utrecht)0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Signed written informed consent;
- •2. Males and females between 18 and 65 years old;
排除标准
- •1. Pregnancy or breastfeeding;
- •2. Severe dermographism;
研究者
相似试验
已完成
不适用
A Phase I study to assess in vitro and in vivo immunoreactivity of Ruconest in Subjects with cow's milk allergy (CMA) and/or rabbit allergy (RA)Cow's milk allergy and rabbit allergy10001708NL-OMON39068Pharming Technologies B.V.25
已完成
1 期
HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected IndividualsHIV InfectionsNCT03485963Catherine Bollard7
已完成
1 期
CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT00087789Sangamo Therapeutics10
已完成
1 期
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaLymphoma, FollicularNCT02631577Hoffmann-La Roche38
招募中
1 期
Study of SYN818 for the Treatment of Advanced or Metastatic Solid TumorsAdvanced Solid CancerMetastatic Solid TumorOvarian CancerBRCA MutationHRR DeficiencyProstate CancerBreast CancerNCT06666270Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30